Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy. If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option.
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Acute myelogenous leukemia (AML) represents a group of acute leukemias that generally express a myeloid phenotype but clinically have heterogeneous and diverse characteristics. At the onset and during treatment of AML, patients are evaluated by clinical risk factors and are considered for allogenic hematopoietic stem cell transplantation (allo-HSCT) based on the risk factors [1, 2] . Cytogenetic abnormality is one of the most widely recognized risk factors in AML patients. AMLs with karyotype t(8;21), inv (16) , t(16;16) and t (15;17) are expected to be controlled by chemotherapy alone, and patients with these AMLs are thus categorized into a favorable cytogenetic risk group [3] . For this reason, indication for allo-HSCT for patients in this group is considered not at the first complete remission (CR1) but at the state of relapse, after the second remission (CR2) or in the case of failure to achieve remission [4, 5, 6, 7] . Although many studies have suggested that cytogenetic risk in AML correlates with the outcome of chemotherapy, the relation between cytogenetic risk and outcome of allo-HSCT is still controversial [8, 9] . These two studies were based on analysis of outcomes in patients who received allo-HSCT with a myeloablative conditioning regimen (conventional stem cell transplantation, CST).
A strategy for allo-HSCT using a reduced-intensity conditioning regimen (reduced-intensity stem cell transplantation, RIST) has been developed and has been used for treatment of patients with AML to reduce regimen-related toxicity (RRT) of the conditioning regimen [10-13].
However, the efficacy and feasibility of RIST for treatment of AML according to cytogenetic risk have not been established. We retrospectively analyzed AML patients treated with RIST in our institute and compared the outcome with that for AML patients who underwent CST.
We report here that RIST for AML patients with favorable cytogenetics is safe and can be effectively performed and that the outcome for AML patients with favorable cytogenetics who received RIST was comparable to that for patients with favorable cytogenetics who underwent CST.
PATIENTS AND METHODS

Patients and preparative regimens
This study was approved by our institutional review board. We 5 retrospectively reviewed the medical records of patients with de novo AML who received allo-HSCT in our hospital. Sixty-nine patients with de novo AML have received allo-HSCT since 1988 ( Figure 1 [19, 20] .
Analysis of efficacy and safety of the treatment
Since the purpose of this study was to analyze the efficacy and safety of RIST for AML, we evaluated overall survival (OS) and relapse-free survival (RFS) rates for AML patients according to cytogenetic risks. OS was calculated from transplantation to death from any cause, and RFS was defined as the time from transplantation to the first event, either relapse or death in complete remission. OS and RFS were analyzed by the Kaplan-Meier method and compared using the log-rank test. We also analyzed early death and cause of death to evaluate the safety.
RESULTS
Characteristics of AML patients who received allo-HSCT
Initially, we analyzed AML patients with favorable cytogenetics who were treated with allo-HSCT. The characteristics of AML patients with favorable cytogenetics who received RIST or CST are shown in Table 1 . Median HCT-CI was 2 in RIST group, and this was significantly higher than that in the CST group, where HCT-CI of all patients was 0 (Mann-Whitney U test, p<0.001).
Next, we analyzed the AML patients with intermediate cytogenetics who were treated with allo-HSCT ( showed engraftment failure and died of RRT during the second CBT.
Patients 37 and 47, who received CST in non-remission status, did not show engraftment because of early growth of leukemia cells.
The duration for neutrophil engraftment varied from 9 to 34 days and the duration for platelet engraftment varied from 12 to 106 days.
Neutrophil engraftment in Patients 10 and 29, who received HSCT in 1988, was day 23 and day 34, respectively. This late engraftment was probably caused by no use of G-CSF, which was not available at the time of transplantation. Except for these two cases, the duration for engraftment seemed to be dependent on the stem cell source.
GVHD and monitoring of MRD
Occurrence of acute and chronic GVHD and the status of MRD in AML patients with favorable cytogenetics are summarized in Table 3 . Acute To exclude the effect of disease status prior to HSCT, we also analyzed patients in hematological remission prior to HSCT (Table 4b) .
Two of the patients who received CST died within 30 days and four patients died within 90 days. The deaths in these four patients were not related to relapse; one death was due to graft failure and three deaths were associated with RRT. As expected, non-relapse mortality rate was lower in the patients who received RIST than in the patients who received CST. In investigation of the efficacy of treatment, it was found that the OS and RFS rates for AML patients with favorable cytogenetics were similar to those for patients who received RIST and patients who received CST (Figures 2a and 2b) . Although age of the patients and HCT-CI were different between the RIST group and CST group, the results suggest that RIST is not inferior to CST for treatment of AML patients with favorable cytogenetics. We also analyzed the effect of cytogenetics on the outcome of allo-HSCT. OS and RFS rates in patients with favorable cytogenetics tended to be better than those in patients with intermediate cytogenetics (Figures 2a and 2b) . Among the patients with favorable cytogenetics, no Patients were subcategorized according to cytogenetic risk [3] . RIST with Favorable Cytogenetics 9 0(0%) 0(0%) 1(11%) 0(0%) 1(11%)
RIST with Intermediate Cytogenetics 8 0(0%) 0(0%) 2(25%) 2(25%) 0(0%) CST with Favorable Cytogenetics 11 1(9%) 0(0%) 1(9%) 0(0%) 2(18%)
CST with Intermediate Cytogenetics 29 4(14%) 3(10%) 6(21%) 4(14%) 9(31%) Table 4 The timing and cause of mortality after allo-HSCT in AML patients with favorable and intermediate cytogenetics RIST with Intermediate Cytogenetics 8 0(0%) 0(0%) 2(25%) 2(25%) 0(0%)
CST with Favorable Cytogenetics 8 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
CST with Intermediate Cytogenetics 20 2(10%) 2(10%) 5(25%) 1(5%) 8(40%)
